Zacks: Azurrx Biopharm (AZRX) Given $8.25 Average Price Target by Brokerages

Shares of Azurrx Biopharm (NASDAQ:AZRX) have been assigned an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.

Brokerages have set a 1-year consensus price target of $8.25 for the company, according to Zacks. Zacks has also assigned Azurrx Biopharm an industry rank of 111 out of 265 based on the ratings given to its competitors.

Separately, HC Wainwright set a $8.00 target price on Azurrx Biopharm and gave the company a “buy” rating in a research report on Friday.

WARNING: This story was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://sportsperspectives.com/2017/11/21/zacks-azurrx-biopharm-azrx-given-8-25-average-price-target-by-brokerages.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AZRX. IHT Wealth Management LLC lifted its position in Azurrx Biopharm by 15.3% during the second quarter. IHT Wealth Management LLC now owns 3,498 shares of the company’s stock valued at $486,000 after purchasing an additional 464 shares in the last quarter. Ardsley Advisory Partners purchased a new position in Azurrx Biopharm during the second quarter valued at $141,000. Parsons Capital Management Inc. RI lifted its position in Azurrx Biopharm by 37.2% during the third quarter. Parsons Capital Management Inc. RI now owns 254,263 shares of the company’s stock valued at $1,015,000 after purchasing an additional 68,920 shares in the last quarter. Finally, Susquehanna International Group LLP purchased a new position in Azurrx Biopharm during the third quarter valued at $131,000. Institutional investors own 6.09% of the company’s stock.

Azurrx Biopharm (NASDAQ:AZRX) traded up $0.13 during midday trading on Friday, reaching $3.04. The company had a trading volume of 41,500 shares, compared to its average volume of 32,986. Azurrx Biopharm has a 12 month low of $2.40 and a 12 month high of $5.25.

Azurrx Biopharm Company Profile

AzurRx BioPharma, Inc is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101.

Get a free copy of the Zacks research report on Azurrx Biopharm (AZRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Azurrx Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azurrx Biopharm and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply